386 related articles for article (PubMed ID: 24685438)
21. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light.
Ruane PH; Edrich R; Gampp D; Keil SD; Leonard RL; Goodrich RP
Transfusion; 2004 Jun; 44(6):877-85. PubMed ID: 15157255
[TBL] [Abstract][Full Text] [Related]
22. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA
Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
[TBL] [Abstract][Full Text] [Related]
23. Proteomic analysis of extracellular vesicles derived from platelet concentrates treated with Mirasol® identifies biomarkers of platelet storage lesion.
Hermida-Nogueira L; Barrachina MN; Izquierdo I; García-Vence M; Lacerenza S; Bravo S; Castrillo A; García Á
J Proteomics; 2020 Jan; 210():103529. PubMed ID: 31605789
[TBL] [Abstract][Full Text] [Related]
24. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.
Apelseth TØ; Bruserud Ø; Wentzel-Larsen T; Bakken AM; Bjørsvik S; Hervig T
Transfusion; 2007 Apr; 47(4):653-65. PubMed ID: 17381624
[TBL] [Abstract][Full Text] [Related]
25. Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion.
Sonego G; Abonnenc M; Tissot JD; Prudent M; Lion N
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208668
[TBL] [Abstract][Full Text] [Related]
26. Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres.
van der Meer PF; Couture C; Hervig T; Kruit G; Devine DV; de Korte D; Kerkhoffs JL
Vox Sang; 2017 Jan; 112(1):9-17. PubMed ID: 28001293
[TBL] [Abstract][Full Text] [Related]
27. Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment.
Schubert P; Culibrk B; Karwal S; Goodrich RP; Devine DV
Proteomics Clin Appl; 2016 Aug; 10(8):839-50. PubMed ID: 27226085
[TBL] [Abstract][Full Text] [Related]
28. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.
Lozano M; Galan A; Mazzara R; Corash L; Escolar G
Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625
[TBL] [Abstract][Full Text] [Related]
29. The impact of refrigerated storage of UVC pathogen inactivated platelet concentrates on in vitro platelet quality parameters.
Johnson L; Cameron M; Waters L; Padula MP; Marks DC
Vox Sang; 2019 Jan; 114(1):47-56. PubMed ID: 30499111
[TBL] [Abstract][Full Text] [Related]
30. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
Seghatchian J; Hervig T; Putter JS
Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
[TBL] [Abstract][Full Text] [Related]
31. Real-time measurement of platelet shape change by light scattering under riboflavin and ultraviolet light treatment.
Terada C; Shiba M; Satake M; Tadokoro K
Transfusion; 2016 Mar; 56(3):587-95. PubMed ID: 26536611
[TBL] [Abstract][Full Text] [Related]
32. Altered timing of riboflavin and ultraviolet light pathogen inactivation improves platelet in vitro quality.
Schubert P; Culibrk B; Karwal S; Serrano K; Levin E; Yi Q; Thiele T; Greinacher A; Marschner S; Devine DV
Transfusion; 2017 Aug; 57(8):2026-2034. PubMed ID: 28500654
[TBL] [Abstract][Full Text] [Related]
33. Bacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation system.
Gravemann U; Handke W; Müller TH; Seltsam A
Transfusion; 2019 Apr; 59(4):1324-1332. PubMed ID: 30588633
[TBL] [Abstract][Full Text] [Related]
34. [Bacterial contamination: should it be detected or inactivated?].
Cazenave JP
Transfus Clin Biol; 2007 May; 14(1):81-5. PubMed ID: 17521943
[TBL] [Abstract][Full Text] [Related]
35. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method.
Sandgren P; Tolksdorf F; Struff WG; Gulliksson H
Vox Sang; 2011 Jul; 101(1):35-43. PubMed ID: 21175668
[TBL] [Abstract][Full Text] [Related]
36. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience.
Lachert E; Kubis J; Antoniewicz-Papis J; Rosiek A; Woźniak J; Piotrowski D; Przybylska Z; Mikołowska A; Marschner S; Łętowska M
Adv Clin Exp Med; 2018 Jun; 27(6):765-772. PubMed ID: 29877637
[TBL] [Abstract][Full Text] [Related]
37. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
38. Pathogen-reduction systems for blood components: the current position and future trends.
Seghatchian J; de Sousa G
Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
[TBL] [Abstract][Full Text] [Related]
39. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
Tauszig ME; Picker SM; Gathof BS
Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of riboflavin and ultraviolet light treatment against Klebsiella pneumoniae in whole blood-derived platelets: A pilot study.
Alabdullatif M; Osman IE; Alrasheed M; Ramirez-Arcos S; Alyousef M; Althawadi S; Alhumiadan H
Transfusion; 2021 May; 61(5):1562-1569. PubMed ID: 33687079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
